U.S. patent application number 15/545996 was filed with the patent office on 2018-01-04 for pcr primer linked to complementary nucleotide sequence or complementary nucleotide sequence including mis-matched nucleotides and method for amplifying nucleic acid using the same.
The applicant listed for this patent is SD BIOSENSOR, INC.. Invention is credited to Sunyoung LEE, Hae-joon PARK, Yoo-Deok WON.
Application Number | 20180002746 15/545996 |
Document ID | / |
Family ID | 56543695 |
Filed Date | 2018-01-04 |
United States Patent
Application |
20180002746 |
Kind Code |
A1 |
WON; Yoo-Deok ; et
al. |
January 4, 2018 |
PCR PRIMER LINKED TO COMPLEMENTARY NUCLEOTIDE SEQUENCE OR
COMPLEMENTARY NUCLEOTIDE SEQUENCE INCLUDING MIS-MATCHED NUCLEOTIDES
AND METHOD FOR AMPLIFYING NUCLEIC ACID USING THE SAME
Abstract
The present invention relates to a primer for PCR obtained by,
directly or through inosine as a linker, linking a complementary
nucleotide sequence or a complementary nucleotide sequence
including a mis-matched nucleotide sequence to the 5'-terminal of a
forward or reverse primer; and to a PCR method including a step of
mixing a nucleic acid template in a PCR composition including the
primer and then performing PCR on the mixture. The primer for PCR
of the present invention includes a complementary nucleotide
sequence or a mis-matched nucleotide sequence in a complementary
nucleotide sequence, which is linked to the 5'-terminal thereof
directly or via a linker, thereby lowering the sensitivity increase
due to the increase in amplification products and reducing
non-specifically occurring reactions in PCR.
Inventors: |
WON; Yoo-Deok; (Yongin-si,
KR) ; PARK; Hae-joon; (Yongin-si, KR) ; LEE;
Sunyoung; (Yongin-sl, KR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SD BIOSENSOR, INC. |
Gyeonggi-do |
|
KR |
|
|
Family ID: |
56543695 |
Appl. No.: |
15/545996 |
Filed: |
January 7, 2016 |
PCT Filed: |
January 7, 2016 |
PCT NO: |
PCT/KR2016/000151 |
371 Date: |
July 24, 2017 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12Q 1/6853 20130101;
C12Q 1/68 20130101; C12Q 1/686 20130101; C12Q 1/6848 20130101; C12Q
1/6848 20130101; C12Q 2525/119 20130101; C12Q 2525/161 20130101;
C12Q 2527/143 20130101 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 30, 2015 |
KR |
10-2015-0015276 |
Claims
1. A primer for gene amplification represented by the following
Structural Formula 1, the primer comprising complementary double
strands of nucleotides with a bubble structure by including a
mis-matched nucleotide linked, directly or by an inosine linker, to
5' terminal of a primer for a corresponding sequence for amplifying
a specific gene sequence: ##STR00002## wherein the primer includes
a complementary nucleotide sequence X.sub.a of the corresponding
sequence for amplifying the specific gene sequence and a
mis-matched nucleotide sequence X'.sub.a which is complementary to
X.sub.a, in which X.sub.a and X'.sub.a are linked with a nucleotide
sequence Y.sub.a of a universal base or a non-discriminatory
base.
2. The primer of claim 1, wherein the primer has the bubble
structure of the mis-matched nucleotide linked with at least one
double-strand sequence.
3. The primer of claim 2, wherein the primer has the bubble
structure of the mis-matched nucleotide linked with one to four
double-strand sequences.
4. The primer of claim 1, wherein a double-strand of X'.sub.a and
X.sub.a of the primer includes at least one bubble structure.
5. The primer of claim 4, wherein the double-strand of X'.sub.a and
X.sub.a of the primer includes one to three bubble structures.
6. The primer of claim 1, wherein the number of the mis-matched
nucleotide in the complementary nucleotide sequence (X'.sub.a) of
the primer is at least one.
7. The primer of claim 6, wherein the number of the mis-matched
nucleotide in the complementary nucleotide sequence (X'.sub.a) of
the primer is 3 to 12.
8. The primer of claim 1, wherein the primer has the bubble
structure including at least 0 universal base or non-discriminatory
base in Y.sub.a of the primer.
9. The primer of claim 8, wherein the primer has the bubble
structure including 0 to 9 universal bases or non-discriminatory
bases in Y.sub.a of the primer.
10. The primer of claim 1, wherein the primer is one or more
primers selected from the group consisting of the primers as set
forth in SEQ ID NOS: 3 to 15, SEQ ID NOS: 18 and 19, and SEQ ID
NOS: 22 to 29.
11. The primer of claim 1, wherein the primer is used in each of
forward and reverse positions for gene amplification or in
both.
12. A method of amplifying a specific gene sequence from RNA,
wherein cDNA is synthesized with a reverse transcription polymerase
for reverse transcription using the primer of claim 1, and the
specific gene is amplified with the cDNA as a template using the
primer of claim 1.
13. The method of claim 12, wherein the method is such that a
specific gene amplification reaction after performing a reverse
transcription of an RNA template using the primer of claim 1 is
carried out in a one-step process.
14. A composition for amplifying a gene used in a polymerase chain
reaction method, a real-time polymerase chain reaction method or an
isothermal amplification method for gene amplification of DNA and
RNA, the composition comprising the primer of claim 1 as an active
ingredient.
15. The composition of claim 14, further comprising one or more
polymerases selected from the group consisting of Taq polymerase
having 5'.fwdarw.3' exonuclease activity, HotStart Taq polymerase,
PFU polymerase, and Klenow polymerase having 5'.fwdarw.3'
exonuclease (-) and 3'.fwdarw.5' exonuclease (-) activity.
16. A kit for amplifying a specific gene for DNA and RNA of an
infectious disease, a hereditary disease, drug tolerance, drug
resistance, and a susceptible test sample, the kit comprising the
primer of claim 1 as an active ingredient.
Description
TECHNICAL FIELD
[0001] The present invention relates to a primer for a nucleic acid
polymerase chain reaction (hereinafter, referred to as "PCR"), in
which the primer includes a complementary nucleotide sequence or a
complementary nucleotide sequence including a mis-matched
nucleotide sequence linked to 5' position of a primer directly or
through a linker and a use thereof, and more specifically to a
primer for PCR obtained by, directly or through inosine as a
linker, linking a complementary nucleotide sequence or a
complementary nucleotide sequence including a mis-matched
nucleotide sequence to 5'-terminal of a forward or reverse primer,
a PCR method including a step of mixing a nucleic acid template in
a PCR composition including the primer and then performing PCR on
the mixture, a complementary primer (CP), and a use thereof.
BACKGROUND ART
[0002] DNA polymerase, primer pair, dNTP, Mg++, and other buffers
are required for PCR components which are essential for molecular
diagnostic test or nucleic acid diagnostic test. The amplification
of the interested target gene having high specificity and accuracy
is required to use such a reaction widely.
[0003] Robust PCR performance requires highly sensitive analytical
PCR such as single-copy DNA molecule detection (Wabuyele, M. B et
al. Single Mol., 2001, 2: 13-21), bloodborne infection (Elnifro, E.
M. et al. Clin. Microbiol. Rev., 2000, 13: 559-570), or the
like.
[0004] Generally, in order to carry out PCR, the information about
the target gene to be detected is obtained, and primer & probe
design is performed. At this time, off-target amplification often
occurs although the primer sequence and length designed are
designed to well hybridize only to template DNA/RNA at annealing
temperatures. It is considered that the reason for this is because
of low-temperature conditions during PCR master-mix preparation and
thermal cycler ramping to the initial denaturation temperature
(Chou, Q et al. Nucleic Acids Res., 1992, 20: 1717-1723). Under
such a condition, the primers are present at a higher concentration
than the target, and the primers react non-specifically with
partially complementary sites, or the primers react with each
other. These non-specific primer complexes competitively react to
the desired target site reaction, thereby impairing sensitivity to
serve as a cause of high background. In particular, primer dimers
may form complex mixtures with primer artifacts during PCR.
[0005] Several methods are widely used for increasing the
specificity of PCR, and one method among them employs a hot start
technique. This technique increases the temperature to maintain the
specificity of the primer/target hybridization reaction so that the
DNA polymerase interferes with the premature extension when
preparing the pre-PCR mixture (Alexandre V. L et al., Lebedev A. V.
et al., Nucleic Acids Res., 2008, 36: e131.). Other methods are
used in which the reaction components are physically separated so
as not to cause a PCR reaction (Quin chou et al., Nucleic Acids
Res., 1992, 20: 1717-1723), accessary proteins are used (Clark, D.
R. et al. US Pat. No. 2006057617), an antibody against a DNA
polymerase is used, and a Mg++-pyrophosphate complex is formed to
prevent a non-specific reaction at a low temperature (Bioneer).
[0006] In addition to increasing the specificity by controlling the
reaction components, several methods have been reported to modify
the primer to increase the specificity. Among them, there are a
method of using to include competitor sequence, a method of using a
secondary structure of a primer, a method of increasing a
hybridization selectivity, and a dual priming oligo method using
two types of primers to be attached to each other (for example,
Seegene). Further, as a 3'-modification method, a method of
blocking primer extension until the 3'->5' exonuclease has been
removed, a method of blocking it by removal through UV irradiation,
and a thermal deprotection method have been reported.
[0007] These methods have the effect of reducing the non-specific
reaction, but they have disadvantages of using additional enzymes,
adding extra activation conditions, specific nucleoside
modification, difficulty in coverage for variants of the
corresponding target gene due to structurally complex primer
design, and a decrease of sensitivity.
PRIOR PATENT DOCUMENT
[0008] Korean Patent Publication No. 10-2004-0005426
DISCLOSURE
Technical Problem
[0009] The present invention has been made to overcome the
above-mentioned problems and in view of the above-mentioned need,
and an object of the present invention is to provide a primer which
reduces the increased sensitivity and non-specific reaction due to
an increase of amplification products in PCR.
[0010] Another object of the present invention is to provide a
method for reducing the increased sensitivity and non-specific
reaction due to an increase of amplification products in PCR.
Technical Solution
[0011] To achieve the objects, the present invention provides a
primer for gene amplification as the following Structural Formula
1, in which the primer includes complementary double strands of
nucleotides with a bubble structure by including a mis-matched
nucleotide linked, directly or by an inosine linker, to 5' terminal
of a primer for a corresponding sequence for amplifying a specific
gene sequence:
##STR00001##
[0012] The primer includes a complementary nucleotide sequence
X.sub.a of the corresponding sequence for amplifying the specific
gene sequence and a mis-matched nucleotide sequence X'.sub.a which
is complementary to X.sub.a, in which X.sub.a and X'.sub.a are
linked with a nucleotide sequence Y.sub.a of a universal base or a
non-discriminatory base.
[0013] In one embodiment of the present invention, the primer is
preferably a primer in which the bubble structure of the
mis-matched nucleotide is linked with at least one double-strand
sequence, and the primer is more preferably a primer in which the
bubble structure of the mis-matched nucleotide is linked with one
to four double-strand sequences, but is not limited thereto.
[0014] In another embodiment of the present invention, a primer
preferably has a structure in which at least one bubble is included
in the double-strand of X'.sub.a and X.sub.a of the primer, and
more preferably has a structure in which one to three bubbles are
included in the double-strand of X'.sub.a and X.sub.a of the
primer, but is not limited thereto.
[0015] In another embodiment of the present invention, the primer
is preferably a primer in which the number of mis-matched
nucleotides in the complementary nucleotide sequence (X'.sub.a)
includes at least one nucleotide sequence, and the primer is more
preferably a primer in which the number of mis-matched nucleotides
in the complementary nucleotide sequence (X'.sub.a) includes 3 to
12 nucleotide sequences, but is not limited thereto.
[0016] In still another embodiment of the present invention, the
primer is preferably a primer having a bubble structure including
at least 0 universal base or non-discriminatory base in Y.sub.a,
and the primer is preferably a primer having a bubble structure
including 0 to 9 universal bases or non-discriminatory bases in
Y.sub.a, but is not limited thereto.
[0017] In one embodiment of the present invention, the primer is
preferably, but not limited to, one or more primers selected from
the group consisting of the primers as set forth in SEQ ID NOS: 3
to 15, SEQ ID NOS: 18 and 19, and SEQ ID NOS: 22 to 29.
[0018] In another embodiment of the present invention, the primer
is used in each of forward and reverse positions for gene
amplification or used in both.
[0019] The present invention also provides a method of amplifying a
specific gene sequence from RNA, in which cDNA is synthesized with
a reverse transcription polymerase for reverse transcription using
the primer of the present invention, and the specific gene is
amplified with the cDNA as a template using the primer of the
present invention.
[0020] In one embodiment of the present invention, the method is
such that the specific gene amplification reaction after performing
the reverse transcription of an RNA template using the primer of
the present invention is preferably carried out in an one-step
process.
[0021] Further, the present invention provides a composition for
amplifying a gene, which is used in a polymerase chain reaction
method, a real-time polymerase chain reaction method, or an
isothermal amplification method for gene amplification of DNA and
RNA, which includes the primer of the present invention as an
active ingredient.
[0022] In one embodiment of the present invention, the composition
preferably further includes one or more polymerases selected from
the group consisting of Taq polymerase having 5'.fwdarw.3'
exonuclease activity, HotStart Taq polymerase, PFU polymerase, and
Klenow polymerase having 5'.fwdarw.3' exonuclease (-) and
3'.fwdarw.5' exonuclease (-) activity, but is not limited
thereto.
[0023] Further, the present invention provides a kit for amplifying
a specific gene for DNA and RNA of an infectious disease, a
hereditary disease, drug tolerance, drug resistance, and a
susceptible test sample, which includes the primer of the present
invention as an active ingredient.
[0024] The primer according to the present invention may also
include a base sequence in which one or more bases are deleted,
substituted or added to the base sequence of each primer and a
primer set.
[0025] The primer and primer set according to the present invention
may include additional features that do not change the basic
properties. That is, the base sequence can be modified using many
means known in the art. Examples of such modifications may include
methylation, capping, substitution of one or more homologs of a
nucleotide, and modification of a nucleotide with an uncharged
linkage such as phosphonate, phosphotriester, phosphoramidate, or
carbamate, or charged linkage such as phosphorothioate or
phosphorodithioate. Further, the nucleic acid may have one or more
residues, which are additionally covalent-bonded, such as a protein
such as a nuclease, a toxin, an antibody, a signal peptide, a
poly-L-lysine, an intercalating agent such as acridine and
psoralen, a chelating agent such as a metal, a radioactive metal,
and an iron-oxidizing metal, and alkylation agent.
[0026] Further, the base sequence of the primer and primer set
according to the present invention can be modified using a label
capable of directly or indirectly providing a detectable signal.
The primer and primer set may include a label that can be detected
using spectroscopic, photochemical, biochemical, immunochemical, or
chemical means. Useful labels include .sup.32P, fluorescent dyes,
electron dense reagents, enzymes (commonly used in ELISAS), biotin
or hapten, and proteins that are available for antisera or
monoclonal antibodies.
[0027] The primer and primer set according to the present invention
can be chemically synthesized using any other well-known method
including a phosphotriester method such as cloning and restriction
enzyme digestion of appropriate sequences and Narang (1979, Meth,
Enzymol. 68: 90-99), a diethylphosphoramidate method such as
Beaucage (1981, Tetrahedron Lett. 22: 1859-1862), and the direct
chemical synthesis methods such as the solid support methods of
U.S. Pat. No. 4,458,066.
[0028] Hereinafter, the present invention will be described.
[0029] The present invention purposes to reduce the increased
sensitivity and non-specifically occurring reaction due to an
increase of amplification products in PCR by a complementary
nucleotide sequence or a complementary nucleotide sequence
including a mis-matched nucleotide sequence linked to 5'-terminal
of the primer for PCR directly or through a linker.
[0030] The present invention relates to a PCR primer including a
complementary nucleotide sequence or a complementary nucleotide
sequence including a mis-matched nucleotide sequence linked to
5'-terminal of the primer directly or through a linker, and more
specifically to a primer for PCR obtained by, directly or through
inosine as a linker, linking a complementary nucleotide sequence or
a complementary nucleotide sequence including a mis-matched
nucleotide sequence to 5'-terminal of a forward or reverse primer,
a PCR method including a step of mixing a nucleic acid template in
a PCR composition including the primer and then performing PCR on
the mixture. The PCR primer of the present invention includes a
complementary nucleotide sequence or a complementary nucleotide
sequence including a mis-matched nucleotide sequence so that there
is the advantage that non-specific reaction occurred in the
amplification reaction can be reduced.
[0031] Hereinafter, the present invention will be described.
[0032] The present invention provides a PCR primer in which a
complementary nucleotide sequence or a complementary nucleotide
sequence including a mis-matched nucleotide sequence is linked to
5'-terminal of a forward or reverse primer directly or through a
linker.
[0033] In the present specification, the term "complementary
nucleotide" refers to a nucleotide having a sequence complementary
to the nucleotide sequence of the forward or reverse primer, and
the direction of the corresponding nucleotide is located at the 5'
terminal of the forward or reverse primer. A "mis-matched
nucleotide sequence" included in a complementary nucleotide refers
to a nucleotide sequence which is mis-matched with a forward or
reverse primer nucleotide sequence. DNA base may be one of adenine,
guanine, cytosine, thymine, and uridine. When the number of
mis-matched nucleotides in the complementary primer is absent, the
Tm value for the primer annealing becomes high, so that the
annealing of the template DNA base sequence is not performed well,
and thus the amplification reaction is not performed. Also, if the
number of mis-matched nucleotides in the complementary primer
exceeds 13, the Tm value of the primer will be significantly
lowered, and the number of mis-matched nucleotides will be
increased, resulting in a non-specific reaction during PCR
execution. Therefore, the primer (CP) of the present invention
generates bubbles according to the number of mis-matched
nucleotides, and the melting Tm decreases as the number of
mis-matched nucleotides increases. Accordingly, one to three
bubbles are formed in the mis-matched nucleotide portion, the
bubble portion, within the complementary sequence.
[0034] The linkage between a primer and the complementary primer
may be directly connected, but a linker may also be used. In this
case, the base used is inosine, and the number of the inosine base
is preferably in the range of 1 to 9, though not particularly
limited. In addition, the present invention provides a composition
for PCR amplification including a DNA polymerase, dNTPs, a buffer
solution for reaction, and the PCR primer.
[0035] As the reaction buffer solution, a conventional PCR buffer
solution including components such as Tris-HCl, KCl,
(NH.sub.4).sub.2SO.sub.4, and MgCl.sub.2 can be suitably modified
and used. The dNTPs refer to dATP, dTTP, dUTP, dGTP, and dCTP, and
the DNA polymerase that can be used is not limited to a specific
enzyme or a hot start effect. In a preferred embodiment of the
present invention, Taq DNA polymerase (5'->3' exo +), Hot start
Taq DNA polymerase (5'->3' exo +), Vent DNA polymerase
(5'->3' exo -), and Pfu DNA polymerase (3'->5' exo +) are
used to perform PCR. Further, the primer for PCR amplification can
be used at a concentration ranging from 0.2 .mu.M to 1 .mu.M, and
suitable primer concentrations can be easily determined by those
skilled in the art.
[0036] The present invention relates to a PCR amplification method
including mixing the nucleic acid template to PCR composition
including a primer and then performing PCR on the mixture, in which
the primer is used as a PCR primer including a complementary
nucleotide sequence or a complementary nucleotide sequence linked a
mis-matched nucleotide sequence in a complementary nucleotide
sequence linked directly or via a linker to the 5'-terminal region
of a primer to be amplified.
[0037] The PCR is carried out by repeating the denaturation,
annealing, and extension steps, and this PCR principle is clear to
the parties. The denaturation, annealing, and elongation,
respectively, are preferably performed at 85.degree. C. to
95.degree. C. for 1 second to 60 seconds, at 40.degree. C. to
70.degree. C. for 1 second to 60 seconds, and at 50.degree. C. to
75.degree. C. for 1 second to 60 seconds, but it can be adjusted
appropriately according to the reaction conditions. For example,
according to a preferred embodiment of the present invention, when
2 to 3 mis-matched nucleotides are substituted in the primer, the
melting temperature (hereinafter, referred to as "Tm") is lowered
by about 5.degree. C. to 10.degree. C., when 4 to 6 mis-matched
nucleotides are substituted in the primer, the melting temperature
(hereinafter, referred to as "Tm") is lowered by about 10.degree.
C. to 20.degree. C., and when 7 to 12 mis-matched nucleotides are
substituted in the primer, the melting temperature (hereinafter,
referred to as "Tm") is lowered by about 20.degree. C. to
30.degree. C. Such a temperature change of Tm may be somewhat
changed depending on the kind of DNA polymerase used, the length of
the primer, the kind of base in the primer, reaction conditions,
and the like. Based on the degree of change in Tm as described
above, it is possible to establish a primer production condition
for imparting temperature equivalence when designing a primer
including a mis-matched nucleotide in a complementary nucleotide
sequence, and to introduce an appropriate number of mis-matched
nucleotides, thereby increasing the specificity of the PCR.
[0038] Using the results of the following embodiments, it is
possible to establish a primer production condition that gives
temperature equivalence at the time of designing a primer for a
primer position and to prepare a nucleotide sequence with a minimal
difference in Tm values to be occurred by introducing a linker and
a mis-matched nucleotide at a proper position in a complementary
nucleotide sequence, thereby increasing the specificity of the PCR
reaction. In addition, PCR specificity and sensitivity can be
maintained with or without exonuclease (5'->3, 3'->5')
function of the DNA polymerase used.
Advantageous Effects
[0039] As described above, by including the mis-matched nucleotide
sequence or the complementary nucleotide sequence directly or via
inosine linker linked to 5' position of a primer, amplification
products are increased in the nucleic acid amplification reaction
using DNA or RNA as a template, so that it is effective to improve
sensitivity and to reduce the nonspecific reaction that occurs.
These effects are all active regardless of the type of DNA
polymerase.
DESCRIPTION OF DRAWINGS
[0040] FIG. 1 is a sequential illustration of a method for
amplifying double-stranded DNA using a primer (CP) of the present
invention.
[0041] FIG. 2 is a sequential illustration of a method for
amplifying single-stranded RNA using a primer (CP) of the present
invention.
[0042] FIG. 3 illustrates a result according to the number of
deoxyinosine included in a bubble portion 1 located at 5'-terminal
of a target region of a primer (CP) of the present invention in a
method of using the primer (CP) of the present invention as one of
two primers necessary for nucleic acid amplification.
[0043] FIGS. 4 and 5 illustrate a result according to the number of
mis-matched nucleotides (0, 3, 7, and 12) in a bubble portion 2
located at a complementary portion of a primer (CP) of the present
invention. FIGS. 4 and 5 illustrate the results according to a
method of using the primer (CP) of the present invention as one of
two primers necessary for nucleic acid amplification.
[0044] FIG. 6 illustrates a result using a primer (CP) of the
present invention in which the number of total bubbles is 2, 3, and
4, respectively by including a bubble portion 1 and bubble portion
2 of a primer (CP) of the present invention in a method of using
the primer (CP) of the present invention as one of two primers
necessary for nucleic acid amplification.
[0045] FIGS. 7 to 10 illustrate a method of using the primer (CP)
of the present invention as one of two primers necessary for
nucleic acid amplification.
[0046] FIG. 7 illustrates a result of using Taq DNA polymerase,
[0047] FIG. 8 illustrates a result of using HotStart Taq DNA
polymerase,
[0048] FIG. 9 illustrates a result of using Pfu DNA polymerase,
and
[0049] FIG. 10 illustrates a result of using Vent DNA
polymerase.
[0050] FIG. 11 illustrates a result of a reaction, as a forward
primer and a reverse primer, using each of two primers necessary
for nucleic acid amplification of a beta-actin gene in human gDNA
as a primer (CP) of the present invention and a result of an
amplification reaction using all two primers necessary for nucleic
acid amplification of a beta-actin gene in human gDNA as a primer
(CP) of the present invention.
[0051] FIG. 12 illustrates a result of an amplification reaction
using the primer (CP) of the present invention as two primers
necessary for nucleic acid amplification of GAPD gene in Rat
gDNA.
[0052] FIGS. 13 to 15 illustrate RT-PCR results depending on the
cDNA synthesis temperature according to the number of mis-matched
nucleotides in a bubble portion 2 located at a complementary region
of a primer (CP) of the present invention.
MODES OF THE INVENTION
[0053] Hereinafter, the present invention will be described in more
detail with reference to examples. However, the following examples
are for illustrative purposes only and are not intended to limit
the scope of the present invention.
Example 1: Analysis of Effects of the Linker of the Bubble Portion
1 of the Primer (CP) of the Present Invention
[0054] DNA template for HIV tat amplification was prepared in which
HIV tat plasmid DNA was prepared by a gene synthesis of HIV-1
isolate 10BR_PE064 (GI: 672918720, 5281-5700 bp) to plasmid
DNA.
[0055] In the primer (CP) of the present invention, the forward
primer and reverse primer for the HIV tat gene of the conventional
method (Nucleic Acids Research, 36:20, 2008) were designed as
target regions, the complementary sequence thereto was positioned
at the 5'-terminal thereof, and the complementary sequence included
7 to 8 mis-matched sequences. The inosine linker was designed as
SEQ ID NOS: 3 to 10 at the bubble portion 1 between the target
region and the complementary sequence. SEQ ID NO: 3 was a primer
including no linker in the bubble portion 1, and SEQ ID NOS: 4 to
10, respectively, were designed to include 1 (Ix1a, Ix1b, Ix1c), 3
(Ix3), 5 (Ix5), 7 (Ix7), and 9 (Ix9) inosine linkers.
[0056] The control group was used a mixture in which SEQ ID NO 1
was used as a forward primer and SEQ ID NO 2 was used as a reverse
primer in the prepared primer. The experimental group was prepared
in a mixture in which the primers (CP) of the present invention of
SEQ ID NOS: 3 to 10 were used as a forward primer and SEQ ID NO 2
was used as a reverse primer.
[0057] The mixture for the nucleic acid amplification reaction
using the primers was prepared in a reaction mixture including 3.0
mM MgCl.sub.2, 0.2 mM dNTPs (NEB), 1.75 U Taq DNA polymerase, 10 ng
Human genomic DNA, and 0.5 M primer set. The nucleic acid
amplification reaction was performed in that 45 ul of the reaction
mixture and 5 ul of the template DNA in 69, 6.9 and 0.69 fg/ul,
respectively, were added, and the initial denaturation step at
94.degree. C. for 10 minutes, the denaturation step at 94.degree.
C. for 30 seconds, the annealing step at 55.degree. C. for 30
seconds, and the extension step at 72.degree. C. for 2 minutes were
carried out for 40 cycles and the final extension step were carried
out at 72.degree. C. for 7 minutes. 5 ul of the amplification
product was subjected to electrophoresis analysis on 2% agarose gel
including gel green dye.
[0058] As a result, as illustrated in FIG. 3, it was exhibited that
amplification products of the primers (CP) of the present invention
(lines 3 of Ix9, Ix7, Ix5, Ix3, Ix1a, Ix1b, Ix1c, and Ix0)
increased as compared with the conventional primer (line 3 of Con)
in lines 3 in which the templates reacted in a concentration of 345
fg. It was exhibited that amplification products of the primers
(CP) of the present invention (lines 2 of Ix7, Ix5, Ix3, Ix1a,
Ix1b, Ix1c, and Ix0) increased as compared with the conventional
primer (line 2 of Con) in lines 2 in which the template
concentration was 34 fg. As a result of the above reaction, Ix1,
Ix3, Ix5 and Ix7 of the primer (CP) of the present invention were
confirmed to exhibit an increase in amplification product compared
to Ix0. Accordingly, the amplification product of the nucleic acid
amplification reaction was confirmed to increase as the inosine was
included in the bubble portion 1 of the primer (CP) of the present
invention.
Example 2: Analysis of Effects According to the Number of
Mis-Matched Sequences on a Bubble Portion 2 of the Primer (CP) of
the Present Invention
[0059] HIV tat plasmid DNA was used as a template. The primer (CP)
of the present invention included one inosine on the bubble portion
1, and then 0, 3, 8, and 12 numbers of mis-matched sequences were
included on the bubble portion 2, thereby preparing SEQ ID NOS: 11,
12, 4, and 13.
[0060] The control group was used a mixture in which SEQ ID NO: 1
was used as a forward primer and SEQ ID NO: 2 was used as a reverse
primer in the prepared primer. The experimental group was prepared
in a mixture in which the primers (CP) of the present invention of
SEQ ID NOS: 11, 12, 4, and 13 were used as a forward primer and SEQ
ID NO: 2 was used as a reverse primer.
[0061] The mixture for the nucleic acid amplification reaction
using the primers was prepared in a reaction mixture including 3.0
mM MgCl.sub.2, 0.2 mM dNTPs, 1.75 U Taq DNA polymerase, 10 ng Human
genomic DNA, and 0.5 .mu.M primer set. The nucleic acid
amplification reaction was performed in that 45 ul of the mixture
and 5 ul of the template DNA in 69, 6.9 and 0.69 fg/ul,
respectively, were added, and the initial denaturation step at
94.degree. C. for 10 minutes, the denaturation step at 94.degree.
C. for 30 seconds, the annealing step at 55.degree. C. for 30
seconds, and the extension step at 72.degree. C. for 2 minutes were
carried out for 40 cycles and the final extension step were carried
out at 72.degree. C. for 7 minutes. 5 ul of the amplification
product was subjected to electrophoresis analysis on 2% agarose gel
including gel green dye.
[0062] M0 illustrated in FIG. 4 was the result of using SEQ ID NO:
11 without the mis-matched sequence as a forward primer and no
amplification product was generated. M3 was SEQ ID NO: 12 including
3 mis-matched sequences, and the amplification product of line 3 of
M3 increased than that of line 3 of Con in lines 3 where 345 fg of
template DNA reacted in the conventional primer (SEQ ID NO: 1).
However, in the lines 2 in which 34.5 fg reacted, the amplification
product was not detected in line 2 of M3.
[0063] M8 illustrated in FIG. 5 was SEQ ID NO: 4 including 8
mis-matched sequences, and M12 was SEQ ID NO: 13 including 12
mis-matched sequences. Their amplification products were confirmed
to be detected in the lines 1 in which the template DNA reacted in
3.45 fg than the conventional primer (SEQ ID NO: 1). In particular,
the amplification product in M8 was confirmed to be the most
increased. As a result, increase and sensitivity enhancement of the
amplification product were confirmed to be depending on the number
of mis-matched sequences on the bubble portion 2 of the primer (CP)
of the present invention.
Example 3: Analysis of Effects According to the Number of Bubbles
of the Primer (CP) of the Present Invention
[0064] The primer (CP) of the present invention includes inosine on
a bubble portion 1 and mis-matched sequence on a bubble portion 2.
The bubble portion 1 formed one bubble, and the bubble portion 2
formed three bubbles.
[0065] SEQ ID NO: 13 produced totally two bubbles, one on the
bubble portion 1 and one on the bubble portion 2. SEQ ID NO: 14
produced one bubble on the bubble portion 1 and two bubbles on the
bubble portion 2. SEQ ID NO: 15 produced one bubble on the bubble
portion 1 and three bubbles on the bubble portion 2. Using the
primer (CP) of the present invention as a forward primer and using
SEQ ID NO: 2 as a reverse primer, the mixture for the nucleic acid
amplification reaction was prepared in a reaction mixture including
3.0 mM MgCl.sub.2, 0.2 mM dNTPs, 1.75 U Taq DNA polymerase, 10 ng
Human genomic DNA, and 0.5 .mu.M primer set.
[0066] The nucleic acid amplification reaction was performed in
that 45 ul of the reaction mixture and 5 ul of the template DNA in
69, 6.9 and 0.69 fg/ul, respectively, were added, and the initial
denaturation step at 94.degree. C. for 10 minutes, the denaturation
step at 94.degree. C. for 30 seconds, the annealing step at
45.degree. C. for 30 seconds, and the extension step at 72.degree.
C. for 2 minutes were carried out for 40 cycles and the final
extension step were carried out at 72.degree. C. for 7 minutes. 5
ul of the amplification product was subjected to electrophoresis
analysis on 2% agarose gel including gel green dye.
[0067] As a result of using the primer (CP) of the present
invention in which the number of bubbles is 2 in each A line, the
number of bubbles is 3 in each B line, and the number of bubbles is
4 in each C line as illustrated in FIG. 6, the amplification
reaction was detected in the lines 2 in which the template DNA was
up to 34.5 fg, in which the number of bubbles was 2 to 4, and the
amplification product was confirmed to increase than the line 3 of
Con in the lines 3 using 345 fg.
Example 4: Analysis of the Amplification Reaction of the Primer
(CP) of the Present Invention by Type of DNA Polymerase
[0068] In order to confirm the amplification reaction of the primer
(CP) of the present invention according to the DNA polymerase used
in the nucleic acid amplification reaction, the primer (CP) of the
present invention of SEQ ID NO: 4 was used as a forward primer, and
SEQ ID NO: 2 was used as a reverse primer. The amplification
reaction was analyzed by Taq DNA polymerase, HotStart Taq DNA
polymerase, Vent DNA polymerase, and Pfu DNA polymerase.
[0069] In the nucleic acid amplification reaction as illustrated in
FIG. 7, the mixture for the nucleic acid amplification reaction of
the Taq DNA polymerase was prepared in a reaction mixture including
3.0 mM MgCl.sub.2, 0.2 mM dNTPs, 1.75 U Taq DNA polymerase, 10 ng
Human genomic DNA, and 0.5 .mu.M primer set.
[0070] In the nucleic acid amplification reaction as illustrated in
FIG. 8, the mixture for the nucleic acid amplification reaction of
the HotStart Taq DNA polymerase was prepared in a reaction mixture
including 3.0 mM MgCl.sub.2, 0.2 mM dNTPs, 1.75 U HotStart Taq DNA
polymerase, 10 ng Human genomic DNA and 0.5 .mu.M primer set.
[0071] In the nucleic acid amplification reaction as illustrated in
FIG. 9, the mixture for the nucleic acid amplification reaction of
the Pfu DNA polymerase was prepared in a reaction mixture including
2.0 mM MgSO.sub.4, 0.2 mM dNTPs, 1.75 U Pfu DNA polymerase, 10 ng
Human genomic DNA and 0.5 .mu.M primer set.
[0072] In the nucleic acid amplification reaction as illustrated in
FIG. 10, the mixture for the nucleic acid amplification reaction of
the Vent DNA polymerase was prepared in a reaction mixture
including 1.times. buffer (20 mM Tris-HCl, 10 mM
(NH.sub.4).sub.2SO.sub.4, 10 mM KCl, 2 mM MgSO.sub.4, 0.01%
TritonX-100, pH 8.8), 0.2 mM dNTPs, 1.75 U Vent DNA polymerase, 10
ng Human genomic DNA, and 0.5 .mu.M primer set.
[0073] The nucleic acid amplification reaction was performed in
that 45 ul of the reaction mixture and 5 ul of the template DNA in
69, 6.9 and 0.69 fg/ul, respectively, were added, and the initial
denaturation step at 94.degree. C. for 10 minutes, the denaturation
step at 94.degree. C. for 30 seconds, the annealing step at
45.degree. C. for 30 seconds, and the extension step at 72.degree.
C. for 2 minutes were carried out for 40 cycles and the final
extension step were carried out at 72.degree. C. for 7 minutes. 5
ul of the amplification product was subjected to electrophoresis
analysis on 2% agarose gel including gel green dye.
[0074] As a result of the Taq DNA polymerase as illustrated in FIG.
7, the amplification product was not confirmed in line 1 of Con
using template DNA 3.45 fg, but the amplification product was
confirmed in line 1 of the primer (CP) of the present
invention.
[0075] As a result of the Hotstart Taq DNA polymerase as
illustrated in FIG. 8, the amplified product in line 2 of the
primer (CP) of the present invention was confirmed to increase as
compared to that in line 2 of Con using template DNA 34.5 fg.
[0076] As a result of the Pfu DNA polymerase as illustrated in FIG.
9, the amplification product was not confirmed in line 2 of Con
using template DNA 34.5 fg, but the amplification product was
confirmed in line 2 of the primer (CP) of the present invention. In
line 1 of Con using template DNA 3.45 fg, many amplified products
of 100 bp or more were detected. However, in line 1 of the primer
(CP) of the present invention, an amplification product of 100 bp
or more could not be confirmed.
[0077] As a result of the Vent DNA polymerase as illustrated in
FIG. 10, exhibited that the amplification products of line 3 of Con
using the template DNA 345 fg and the line 3 of the primer (CP) of
the present invention exhibited similar band thicknesses, but all
of the lines 1, 2, and 3 exhibited a drag phenomenon, and the lines
1, 2 and 3 of the primer (CP) of the present invention exhibited no
drag phenomenon.
Example 5: Analysis of Amplification Reaction According to the
Application of Each or Pair of the Forward and Reverse Primers of
the Primer (CP) of the Present Invention
[0078] As illustrated in FIG. 11, the nucleic acid amplification
reaction was carried out in which and SEQ ID NO: 16 was a forward
primer and SEQ ID NO: 17 was a reverse primer in Con line, a primer
of the conventional method (Nucleic Acids Research, 36:20, 2008)
for amplification of the beta actin gene of human genomic DNA.
[0079] The primer (CP) of the present invention includes one
inosine in the bubble portion 1 and four mis-matched sequences in
the bubble portion 2 to produce the primer (CP) of the present
invention having SEQ ID NO: 18 and SEQ ID NO: 19 for SEQ ID NO: 16
and SEQ ID NO: 17.
[0080] Using the primer (CP) of the present invention, the nucleic
acid amplification reaction was carried out in which SEQ ID NO: 18
of the primer (CP) of the present invention was used as a forward
primer and a conventional SEQ ID NO: 17 primer was used as a
reverse primer in A_F line as illustrated in FIG. 11, and the
nucleic acid amplification reaction was carried out in which SEQ ID
NO: 16 of the conventional primer, was used as a forward primer,
and SEQ ID NO: 19 of the primer (CP) of the present invention, was
used as a reverse primer in A_R line. In A_F&R line, SEQ ID NO:
18 and SEQ ID NO: 19 of the primer (CP) of the present invention,
were used as a forward and reverse primers, respectively.
[0081] The mixture of the nucleic acid amplification reaction for
the primer set was prepared in a reaction mixture including 2.5 mM
MgCl.sub.2, 0.2 mM dNTPs, 1.25 U Taq DNA polymerase, and 0.5 .mu.M
primer set.
[0082] The reaction mixture and 100, 10, and 1 ng, respectively, of
human genomic DNA (Promega, G3041) were added and then total 50 ul
of reaction product was subject to the nucleic acid amplification
reaction in which the initial denaturation step at 94.degree. C.
for 2 minutes, the denaturation step at 94.degree. C. for 30
seconds, the annealing step at 60.degree. C. for 30 seconds, and
the extension step at 72.degree. C. for 45 seconds were carried out
for 40 cycles and the final extension step were carried out at
72.degree. C. for 7 minutes. 5 ul of the amplification product was
subjected to electrophoresis analysis on 2% agarose gel including
gel green dye.
[0083] As a result according to the nucleic acid amplification
reaction, a single-band amplification products of the A_F, A_R, and
A_F & R lines using the primer (CP) of the present invention
were exhibited, and there or more bands, as the amplification
products, in the Con line using the conventional primer were
exhibited. The amplification product for the beta actin gene was a
single amplification product corresponding to 653 bp, and the
result according to the primer (CP) of the present invention of
FIG. 11 is confirmed to be higher than specificity of the
conventional primer. The specificity of the primer (CP) of the
present invention was confirmed to increase even when only one of
the forward and reverse primers was applied. The increasing effect
of the amplification product was confirmed when the primer (CP) of
the present invention was applied to only one of the two primers,
and the increase of the amplification product was also confirmed
when using a pair of primers.
[0084] As illustrated in FIG. 12, for amplifying the GAPD gene of
Rat genomic DNA, SEQ ID NO: 20 of (Nucleic Acids Research, 36:20,
2008) CP was used as a forward primer, and SEQ ID NO: 21 was used
as a reverse primer. SEQ ID NO: 22 of 6 mis-matched sequences in
the bubble portion 2 and SEQ ID NO: 24 of 10 mis-matched sequences
in the bubble portion 2 were used as a forward primer, and SEQ ID
NO: 23 of 8 mis-matched sequences and SEQ ID NO: 25 of 10
mis-matched sequences were used as a reverse primer in the primer
(CP) of the present invention
[0085] The mixture of the nucleic acid amplification reaction for
the primer set was prepared in a reaction mixture including 2.0 mM
MgCl.sub.2, 0.2 mM dNTPs, 1 U Taq DNA polymerase, and 0.5 .mu.M
primer set.
[0086] The reaction mixture and 1000, 100, 10, and 1 pg,
respectively, of Rat genomic DNA (Clonetech, Cat. No. 636404) were
added and then total 25 ul of reaction product was subject to the
nucleic acid amplification reaction in which the initial
denaturation step at 94.degree. C. for 5 minutes, the denaturation
step at 94.degree. C. for 30 seconds, the annealing step at
55.degree. C. for 30 seconds, and the extension step at 72.degree.
C. for 30 seconds were carried out for 35 cycles and the final
extension step were carried out at 72.degree. C. for 7 minutes. 5
ul of the amplification product was subjected to electrophoresis
analysis on 2% agarose gel including gel green dye.
[0087] The line 1 illustrated in FIG. 12 is the amplification
product of the nucleic acid amplification reaction using 1 pg of
Rat genomic DNA. It was confirmed that the amplification products
of the lines 1 of M6 and M8 for SEQ ID NO: 22 and SEQ ID NO: 23,
respectively, in which 6 and 8 mis-matched sequences were applied
to the bubble portion 2 of the primer (CP) of the present invention
and the lines 1 of M10 and M10 for SEQ ID NO: 24 and SEQ ID NO: 25,
respectively, in which 10 and 10 mis-matched sequences were applied
to the bubble portion 2 of the primer (CP) of the present invention
increased to compared with the line 1 of Con. As a result of the
above-mentioned 11 and 12, it was confirmed that when the primer
(CP) of the present invention applied to only one or two pairs
among the pairs of primer for the nucleic acid amplification
reaction results in an increase of the specificity and the
amplification product. The increase in the amplification product
was also confirmed in the combination of two pairs of primers (CP)
of the present invention having different mis-matched sequence
numbers of the primer (CP) of the present invention.
Example 6: Verification of Amplification Efficiency of RT-PCR Using
the Primer (CP) of the Present Invention
[0088] RT-PCR was performed using a conventional primer (Nucleic
Acids Research, 36:20, 2008) and the primer (CP) of the present
invention to amplify the beta actin gene in human total RNA
(Stratagene, Cat. No. 750500). In order to synthesize RNA into cDNA
as the first step of RT-PCR, SEQ ID NO: 17 corresponding to the
reverse primer of the conventional primer set was used, and, cDNA
was synthesized using SEQ ID NO: 19 with 4 mis-matched sequences,
SEQ ID NO: 27 with 6 mis-matched sequences, and SEQ ID NO: 29 with
8 mis-matched sequences, respectively, in the bubble portion 2 of
the primer (CP) of the present invention.
[0089] For cDNA synthesis, a mixture was prepared to include
1.times. buffer (50 mM Tris-HCl, pH 8.3, 3 mM MgCl.sub.2, 10 mM
DTT, 75 mM KCl), 2 mM dNTPs, 1 M primer, 200 U M-MLV RTase, and
Human total RNA 40, 4, 0.4 ng.
[0090] The mixture for cDNA synthesis reaction reacted at
45.degree. C., 55.degree. C., and 65.degree. C., respectively, for
60 minutes, and then the M-MLV RTase was inactivated at 94.degree.
C. for 5 minutes. The nucleic acid amplification reaction was
carried out, in which the cDNA reaction solution was used as a
template, and SEQ ID NO: 16 and SEQ ID NO: 17 were used as a primer
set for the reaction solution synthesized in SEQ ID NO: 17, SEQ ID
NO: 18 and SEQ ID NO: 19 were used as a primer set for the reaction
solution synthesized in SEQ ID NO: 19, SEQ ID NO: 26 and SEQ ID NO:
27 were used as a primer set for the reaction solution synthesized
in SEQ ID NO: 27, and SEQ ID NO: 28 and SEQ ID NO: 29 were used as
a primer set for the reaction solution synthesized in SEQ ID NO:
29, respectively.
[0091] The mixture of the nucleic acid amplification reaction for
the primer set was prepared in a reaction mixture including 2.5 mM
MgCl.sub.2, 0.2 mM dNTPs, 1.25 U Taq DNA polymerase, and 0.5 M
primer set.
[0092] The reaction mixture and each 5 ul of cDNA reaction solution
(2, 0.2, and 0.02 ng) of each primer for Human total RNA were added
and then total 50 ul of the reaction product was subject to the
nucleic acid amplification reaction in which the initial
denaturation step at 94.degree. C. for 2 minutes, the denaturation
step at 94.degree. C. for 30 seconds, the annealing step at
60.degree. C. for 30 seconds, and the extension step at 72.degree.
C. for 45 seconds were carried out for 40 cycles and the final
extension step were carried out at 72.degree. C. for 7 minutes. 5
ul of the amplification product was subjected to electrophoresis
analysis on 2% agarose gel including gel green dye.
[0093] FIG. 13 illustrates the result of carrying out the cDNA
synthesis reaction at 65.degree. C., and the amplification products
of A, B, and C lines, respectively, including 4, 6, and 8
mis-matched sequences in the bubble portion 2 of the primer (CP) of
the present invention were confirmed to increase compared to the
conventional primer Con line. FIG. 14 illustrates the result of
carrying out the cDNA synthesis reaction at 55.degree. C., and the
amplification products of the primer (CP) of the present invention
was confirmed to increase compared to that of the conventional
primer, and that the amplification product of line 1 of C including
8 mis-matched sequences increased compared to those of the lines 1
of Con, A, and B. FIG. 15 illustrates the result of carrying out
the cDNA synthesis reaction at 45.degree. C., and the amplification
products of the primer (CP) of the present invention was confirmed
to increase compared to that of the conventional primer, and that
the amplification products of the line 1 of C including 6 and 8
mis-matched sequences increased compared to those of the lines 1 of
Con and A. As a result, the reactivity of the primer (CP) of the
present invention was confirmed to increase as compared with the
conventional primer set according to the temperature range during
cDNA synthesis. Therefore, the primer (CP) of the present invention
was used to confirm the usefulness of an amplification reaction of
a specific gene by RT-PCR in single-stranded RNA.
Sequence CWU 1
1
29125DNAArtificial SequenceTatF 1gaattgggtg tcaacatagc agaat
25227DNAArtificial SequenceTatR 2aatactatgg tccacacaac tattgct
27350DNAArtificial SequenceTat55 F-Ix0 3attctgctta caactgaccc
aattcgaatt gggtgtcaac atagcagaat 50451DNAArtificial SequenceTat55
F-Ix1modified_base(26)..(26)misc_feature(26)..(26)n is a, c, g, or
t 4attctgctta caactgaccc aattcngaat tgggtgtcaa catagcagaa t
51551DNAArtificial SequenceTat55
F-Ix1_5modified_base(26)..(26)misc_feature(26)..(26)n is a, c, g,
or t 5attcacgata cttgacaccc aattcngaat tgggtgtcaa catagcagaa t
51651DNAArtificial SequenceTat55
F-Ix1_3modified_base(26)..(26)misc_feature(26)..(26)n is a, c, g,
or t 6attctgctta caactgaccc aattcngaat tgggtgtcaa catagcagaa t
51753DNAArtificial SequenceTat55
F-Ix3modified_base(26)..(28)misc_feature(26)..(28)n is a, c, g, or
t 7attctgctta caactgaccc aattcnnnga attgggtgtc aacatagcag aat
53855DNAArtificial SequenceTat55
F-Ix5modified_base(26)..(30)misc_feature(26)..(30)n is a, c, g, or
t 8attctgctta caactgaccc aattcnnnnn gaattgggtg tcaacatagc agaat
55957DNAArtificial SequenceTat55
F-Ix7modified_base(26)..(32)misc_feature(26)..(32)n is a, c, g, or
t 9attctgctta caactgaccc aattcnnnnn nngaattggg tgtcaacata gcagaat
571059DNAArtificial SequenceTat55
F-Ix9modified_base(26)..(34)misc_feature(26)..(34)n is a, c, g, or
t 10attctgctta caactgaccc aattcnnnnn nnnngaattg ggtgtcaaca
tagcagaat 591151DNAArtificial SequenceTat
F-Ix1modified_base(26)..(26)misc_feature(26)..(26)n is a, c, g, or
t 11attctgctat gttgacaccc aattcngaat tgggtgtcaa catagcagaa t
511251DNAArtificial SequenceTat65
F-Ix1modified_base(26)..(26)misc_feature(26)..(26)n is a, c, g, or
t 12attctgctat caagacaccc aattcngaat tgggtgtcaa catagcagaa t
511351DNAArtificial SequenceTat45
F-Ix1modified_base(26)..(26)misc_feature(26)..(26)n is a, c, g, or
t 13attctggata caactgtgcc aattcngaat tgggtgtcaa catagcagaa t
511451DNAArtificial SequenceTat45
F-Ix1_53modified_base(26)..(26)misc_feature(26)..(26)n is a, c, g,
or t 14attcacgtat gttgactggc aattcngaat tgggtgtcaa catagcagaa t
511551DNAArtificial SequenceTat45
F-Ix1_53-4modified_base(26)..(26)misc_feature(26)..(26)n is a, c,
g, or t 15attctgctta caactgtggc aattcngaat tgggtgtcaa catagcagaa t
511620DNAArtificial SequenceBeta-actin_F 16agagatggcc acggctgctt
201720DNAArtificial SequenceBeta-actin_R 17atttgcggtg gacgatggag
201841DNAArtificial SequenceB-actin65
F-Ix1modified_base(21)..(21)misc_feature(21)..(21)n is a, c, g, or
t 18aagcagccca ccccatctct nagagatggc cacggctgct t
411941DNAArtificial SequenceB-actin65
R-Ix1modified_base(21)..(21)misc_feature(21)..(21)n is a, c, g, or
t 19ctccatcgtg gtgcgcaaat natttgcggt ggacgatgga g
412020DNAArtificial SequenceGAPD N_F 20accacagtcc atgccatcac
202121DNAArtificial SequenceGAPD N_R 21tcccaccacc ctgttgctgt a
212241DNAArtificial SequenceGAPD55
F-Ix1modified_base(21)..(21)misc_feature(21)..(21)n is a, c, g, or
t 22gtgatgggta cctctgtggt naccacagtc catgccatca c
412343DNAArtificial SequenceGAPD55
R-Ix1modified_base(22)..(22)misc_feature(22)..(22)n is a, c, g, or
t 23tacagcatgt cccacgtggg antcccacca ccctgttgct gta
432441DNAArtificial SequenceGAPD45
F-Ix1-2modified_base(21)..(21)misc_feature(21)..(21)n is a, c, g,
or t 24gtgatgcgta cctgactggt naccacagtc catgccatca c
412543DNAArtificial SequenceGAPD45
R-Ix1-2modified_base(22)..(22)misc_feature(22)..(22)n is a, c, g,
or t 25tacagcttgt cccacctggg antcccacca ccctgttgct gta
432641DNAArtificial SequenceB-actin55
F-Ix1modified_base(21)..(21)misc_feature(21)..(21)n is a, c, g, or
t 26aagcagcgca ccgcatctct nagagatggc cacggctgct t
412741DNAArtificial SequenceB-actin55
R-Ix1modified_base(21)..(21)misc_feature(21)..(21)n is a, c, g, or
t 27ctccatccag ctgcgcaaat natttgcggt ggacgatgga g
412841DNAArtificial SequenceB-actin45
F-Ix1modified_base(21)..(21)misc_feature(21)..(21)n is a, c, g, or
t 28aagcacggca ccggatctct nagagatggc cacggctgct t
412941DNAArtificial SequenceB-actin45
R-Ix1modified_base(21)..(21)misc_feature(21)..(21)n is a, c, g, or
t 29ctccatgtag ctgggcaaat natttgcggt ggacgatgga g 41
* * * * *